Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.33 |
| ▸ | NOX1 | Q9Y5S8 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL27892000 | 1.00 | SNCA (0.47) | SNCAMAPTNOX1MEN1KMT2A | |
| SCHEMBL13556668 | 0.98 | SNCA (0.48) | SNCAMAPTNOX1MEN1KMT2A | |
| SCHEMBL2594080 | 0.82 | SNCA (0.31) | SNCA | |
| SCHEMBL20495635 | 0.81 | SNCA (0.50) | SNCAMAPTNOX1MEN1KMT2A | |
| Bromide SCHEMBL30448580 | 0.80 | SNCA (0.64) | SNCAMAPTNOX1MEN1KMT2A | |
| Bromide SCHEMBL20495634 | 0.80 | SNCA (0.64) | SNCAMAPTNOX1MEN1KMT2A | |
| Bromide SCHEMBL9932410 | 0.80 | SNCA (0.43) | SNCAMAPTNOX1MEN1KMT2A | |
| Bromide SCHEMBL27892037 | 0.80 | SNCA (0.43) | SNCAMAPTNOX1MEN1KMT2A | |
| Bromide SCHEMBL2588568 | 0.80 | SNCA (0.43) | SNCAMAPTNOX1MEN1KMT2A | |
| SCHEMBL12274011 | 0.79 | SNCA (0.48) | SNCAMAPTNOX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585073-B1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8809317-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8785434-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2585073-A1 | ANTIVIRAL COMPOUNDS | Prostetta Antiviral Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20120302556-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012135402-A1 | ANTIVIRAL COMPOUNDS | PROSTETTA ANTIVIRAL INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120157435-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011137447-A1 | ANTIVIRAL COMPOUNDS | PROSTETTA ANTIVIRAL INC. (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157435-A1 | Antiviral Compounds | MAVS, ZC3HAV1, EIF2AK2 | SNCA 1569/4885MAPT 693/4885NOX1 2140/4885 |
| US-20120302556-A1 | Antiviral Compounds | HAVCR2, MAVS, EIF2AK2 | SNCA 734/4885MAPT 1569/4885NOX1 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.